Previous Page  29 / 32 Next Page
Information
Show Menu
Previous Page 29 / 32 Next Page
Page Background

Rationale for using 1

st

-2

nd

generation EGFR TKI first

•

Good treatment outcomes with sequential

1

st

-2

nd

generation

followed

by osimertinib in T790M+

•

Resistance mechanism after PD with 1L osimertinib

•

Appropriate therapy after 1L osimertinib PD, not well defined